Agilent Technologies Inc. (NYSE: A) received U.S. Food and Drug Administration approval to expand use of its PD-L1 IHC 22C3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE